341 related articles for article (PubMed ID: 23055714)
1. Exacerbation frequency and course of COPD.
Halpin DM; Decramer M; Celli B; Kesten S; Liu D; Tashkin DP
Int J Chron Obstruct Pulmon Dis; 2012; 7():653-61. PubMed ID: 23055714
[TBL] [Abstract][Full Text] [Related]
2. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
[TBL] [Abstract][Full Text] [Related]
3. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
[TBL] [Abstract][Full Text] [Related]
4. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes.
Anzueto A; Leimer I; Kesten S
Int J Chron Obstruct Pulmon Dis; 2009; 4():245-51. PubMed ID: 19657398
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance.
Ambrosino N; Foglio K; Balzano G; Paggiaro PL; Lessi P; Kesten S;
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):771-80. PubMed ID: 19281092
[TBL] [Abstract][Full Text] [Related]
6. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial.
Tashkin D; Celli B; Kesten S; Lystig T; Decramer M
Respir Med; 2010 Oct; 104(10):1495-504. PubMed ID: 20418083
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.
Troosters T; Celli B; Lystig T; Kesten S; Mehra S; Tashkin DP; Decramer M;
Eur Respir J; 2010 Jul; 36(1):65-73. PubMed ID: 20185426
[TBL] [Abstract][Full Text] [Related]
9. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).
Morice AH; Celli B; Kesten S; Lystig T; Tashkin D; Decramer M
Respir Med; 2010 Nov; 104(11):1659-67. PubMed ID: 20724131
[TBL] [Abstract][Full Text] [Related]
10. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009285. PubMed ID: 25046211
[TBL] [Abstract][Full Text] [Related]
11. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial.
Hanania NA; Sharafkhaneh A; Celli B; Decramer M; Lystig T; Kesten S; Tashkin D
Respir Res; 2011 Jan; 12(1):6. PubMed ID: 21219660
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials.
Cooper CB; Anzueto A; Decramer M; Celli B; Tashkin DP; Leimer I; Kesten S
Int J Chron Obstruct Pulmon Dis; 2011; 6():269-75. PubMed ID: 21845038
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses.
Tashkin D; Kesten S
Chest; 2003 May; 123(5):1441-9. PubMed ID: 12740259
[TBL] [Abstract][Full Text] [Related]
14. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
Tashkin DP
Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
[TBL] [Abstract][Full Text] [Related]
15. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
[TBL] [Abstract][Full Text] [Related]
16. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
Vincken W; van Noord JA; Greefhorst AP; Bantje TA; Kesten S; Korducki L; Cornelissen PJ;
Eur Respir J; 2002 Feb; 19(2):209-16. PubMed ID: 11871363
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.
Fukuchi Y; Fernandez L; Kuo HP; Mahayiddin A; Celli B; Decramer M; Kesten S; Liu D; Tashkin D
Respirology; 2011 Jul; 16(5):825-35. PubMed ID: 21539680
[TBL] [Abstract][Full Text] [Related]
18. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.
Tonnel AB; Perez T; Grosbois JM; Verkindre C; Bravo ML; Brun M;
Int J Chron Obstruct Pulmon Dis; 2008; 3(2):301-10. PubMed ID: 18686739
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
Ma J; Zhou Z; Tang Y; Zhong N
Zhonghua Nei Ke Za Zhi; 2014 Dec; 53(12):964-8. PubMed ID: 25623564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
